Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Phase 4

Recruiting

Conditions: Non-Small Cell Lung Cancer Metastatic

Interventions: Drug: Atezolizumab
Drug: Pembrolizumab
Drug: Nab paclitaxel
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2023-01-19

Last Posted Date: 2024-10-26

Lead Sponsor: Nikolaj Frost MD

Target Recruit Count: 136

Registration Number: NCT05689671

Locations: 🇩🇪
LungenClinic Großhansdorf GmbH, Großhansdorf, Germany
🇩🇪
Universitätsmedizin Göttingen, Göttingen, Germany
🇩🇪
Asklepios Klinkum Hamburg, Hamburg, Germany

and more 28 locations

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Behavioral: Standard of Care
Behavioral: Questionnaires
Radiation: Cisplatin
Radiation: Carboplatin

First Posted Date: 2023-01-11

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT05681039

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of PT217 in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phase 1

Recruiting

Conditions: Small Cell Lung Cancer (SCLC)
Large Cell Neuroendocrine Cancer (LCNEC)
Neuroendocrine Prostate Cancer (NEPC)
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Neuroendocrine Carcinomas (NEC)
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

Interventions: Drug: PT217
Drug: Carboplatin + Etoposide
Drug: Paclitaxel.
Drug: Atezolizumab

First Posted Date: 2022-12-15

Last Posted Date: 2024-11-22

Lead Sponsor: Phanes Therapeutics

Target Recruit Count: 203

Registration Number: NCT05652686

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 4 locations

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Phase 2

Active, not recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Atezolizumab
Drug: Tobemstomig
Drug: Tiragolumab

First Posted Date: 2022-12-09

Last Posted Date: 2024-11-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 210

Registration Number: NCT05645692

Locations: 🇦🇺
Lyell McEwin Hospital, Adelaide, South Australia, Australia
🇺🇸
University of Alabama At Birmingham, Birmingham, Alabama, United States
🇫🇷
Centre Eugène Marquis, Rennes, France

and more 81 locations

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Phase 1

Recruiting

Conditions: SCLC,Extensive Stage

Interventions: Drug: RYZ101 Dose Level 1
Drug: RYZ101 Dose Level 2
Drug: RYZ101 Dose Level 3
Drug: RYZ101 Dose Level -1
Drug: Atezolizumab
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2022-10-27

Last Posted Date: 2024-08-23

Lead Sponsor: RayzeBio, Inc.

Target Recruit Count: 31

Registration Number: NCT05595460

Locations: 🇵🇷
Research Facility, San Juan, Puerto Rico

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Solid Tumors
NSCLC
HNSCC
Melanoma
TNBC
Esophageal Cancer
Gastric Cancer
Cervical Cancer
Colorectal Cancer
Urothelial Carcinoma

Interventions: Drug: RO7502175
Drug: Atezolizumab
Drug: Pembrolizumab

First Posted Date: 2022-10-14

Last Posted Date: 2024-11-22

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 450

Registration Number: NCT05581004

Locations: 🇪🇸
Hospital Universitario 12 De Octubre, Madrid, Spain
🇪🇸
Hospital Universitario Virgen de la Victoria, Malaga, Spain
🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain

and more 30 locations